PARCOPA ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00590122 (ClinicalTrials.gov)	October 2006	28/12/2007	Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study	COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL	Parkinson's Disease	Drug: Parcopa;Drug: carbidopa-levodopa	Baylor College of Medicine	UCB Pharma	Completed	31 Years	80 Years	Both	20	Phase 4	United States
2	NCT00139880 (ClinicalTrials.gov)	June 2005	29/8/2005	A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease	A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease	Parkinson's Disease	Drug: Parcopa	UCB Pharma	NULL	Completed	40 Years	N/A	Both		Phase 3	United States
3	NCT00139867 (ClinicalTrials.gov)	January 2004	29/8/2005	A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease	A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease	Parkinson's Disease	Drug: PARCOPA	UCB Pharma	NULL	Completed	18 Years	N/A	Both		Phase 3	United States